Tabynov Kairat, Turebekov Nurkeldi, Babayeva Meruert, Fomin Gleb, Yerubayev Toktassyn, Yespolov Tlektes, Li Lei, Renukaradhya Gourapura J, Petrovsky Nikolai, Tabynov Kaissar
International Center for Vaccinology, Kazakh National Agrarian Research University (KazNARU), Almaty, Kazakhstan.
Preclinical Research Laboratory with Vivarium, M. Aikimbayev National Research Center for Especially Dangerous Infections, Almaty, Kazakhstan.
NPJ Vaccines. 2022 Feb 23;7(1):24. doi: 10.1038/s41541-022-00450-8.
Recombinant protein approaches offer major promise for safe and effective vaccine prevention of SARS-CoV-2 infection. We developed a recombinant spike protein vaccine (called NARUVAX-C19) and characterized its ability when formulated with a nanoemulsion adjuvant to induce anti-spike antibody and T-cell responses and provide protection including against viral transmission in rodent. In mice, NARUVAX-C19 vaccine administered intramuscularly twice at 21-day interval elicited balanced Th1/Th2 humoral and T-cell responses with high titers of neutralizing antibodies against wild-type (D614G) and delta (B.1.617.2) variants. In Syrian hamsters, NARUVAX-C19 provided complete protection against wild-type (D614G) infection and prevented its transmission to naïve animals (n = 2/group) placed in the same cage as challenged animals (n = 6/group). The results contrasted with only weak protection seen with a monomeric spike receptor-binding domain (RBD) vaccine even when formulated with the same adjuvant. These encouraging results warrant the ongoing development of this COVID-19 vaccine candidate.
重组蛋白方法为安全有效地预防SARS-CoV-2感染的疫苗带来了重大希望。我们开发了一种重组刺突蛋白疫苗（称为NARUVAX-C19），并对其与纳米乳佐剂配制时诱导抗刺突抗体和T细胞反应以及提供保护（包括在啮齿动物中防止病毒传播）的能力进行了表征。在小鼠中，以21天的间隔肌肉注射两次NARUVAX-C19疫苗，可引发平衡的Th1/Th2体液和T细胞反应，并产生针对野生型（D614G）和德尔塔（B.1.617.2）变体的高滴度中和抗体。在叙利亚仓鼠中，NARUVAX-C19提供了针对野生型（D614G）感染的完全保护，并防止其传播给与受挑战动物（每组6只）置于同一笼子中的未感染动物（每组2只）。即使与相同的佐剂配制，结果与单体刺突受体结合域（RBD）疫苗所见的微弱保护形成对比。这些令人鼓舞的结果保证了这种COVID-19候选疫苗的持续开发。
